Patents Represented by Attorney Samuel J. DuBoff
  • Patent number: 8343477
    Abstract: Macrocyclic peptides are disclosed having the general formula: wherein R3, R?3, R4, R6, R?, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: January 1, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stanley D'Andrea, Zhizhen Barbara Zheng, Paul Michael Scola
  • Patent number: 7083973
    Abstract: The present invention relates to a process for the stereoselective enzymatic reduction of 1-halo-2-oxo-3-(protected)amino-4-substituted-butanes utilizing certain species of Rhodococcus and Brevibacterium. The product 1-halo-2-hydroxy-3-(protected)amino-4-substituted-butanes, which are useful as intermediates in the synthesis of compounds that are inhibitors of ACE, renin and HIV proteases, are obtained in high yield and, particularly, in very high diastereomeric purity. The process is advantageously highly selective for the (3S,2R) enantiomer of the product.
    Type: Grant
    Filed: September 12, 2003
    Date of Patent: August 1, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ramesh N. Patel, Linda Chu
  • Patent number: 7037913
    Abstract: This invention provides compounds of Formula I having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with amido piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
    Type: Grant
    Filed: March 20, 2003
    Date of Patent: May 2, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Owen B. Wallace, Nicholas A. Meanwell, John F. Kadow, Zhongxing Zhang, Zhong Yang
  • Patent number: 6900323
    Abstract: The invention comprises novel azaindole intermediate compounds useful in the preparation of compounds of the class of azaindole piperazine diamide derivatives, composition thereof and their use as anti-viral agents, and particularly for treating HIV infection.
    Type: Grant
    Filed: July 16, 2003
    Date of Patent: May 31, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Owen B. Wallace, Zhongxing Zhang, Nicholas A. Meanwell, John A. Bender
  • Patent number: 6900206
    Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with sulfonylureido piperazine derivatives of Formula I. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS. wherein: Z is Q is selected from the group consisting of: —W— is — represents a carbon-carbon bond or does not exist; and A is NR13R14.
    Type: Grant
    Filed: June 9, 2003
    Date of Patent: May 31, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: John F. Kadow, Alicia Regueiro-Ren, Qiufen May Xue
  • Patent number: 6825201
    Abstract: The invention comprises substituted indole, azaindole and related heterocyclic amidopiperazine derivatives of general Formula I wherein: Q is —may represent a bond; A is selected from the group consisting of C1-6alkoxy, C1-6alkyl, C3-7cycloalkyl, phenyl, and heteroaryl; wherein said heteroaryl may be monocyclic or bicyclic and may be comprised of three to eleven atoms selected from the group consisting of C, N, NR9, O, and S, and wherein each ring of said phenyl and heteroaryl is optionally substituted with one to five same or different substituents selected from the group consisting of R19-R23; T is U is NR7, O, or S; V is C(H)kR1, O or N(R7′)k; W is CR3 or NR10; X is CR4 or NR10; Y is CR5 or NR10; Z is CR6 or NR10; k is 0 or 1; and m, n, and p are each independently 0, 1, or 2 provided that the sum of m, n, and p must equal 1 or 2; compositions thereof and their use as antiviral agents, particularly for treating HIV infection.
    Type: Grant
    Filed: April 22, 2002
    Date of Patent: November 30, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Owen B. Wallace, Nicholas A. Meanwell, Zhongxing Zhang, John A. Bender, John F. Kadow, Kap-Sun Yeung
  • Patent number: 6818643
    Abstract: The present invention relates to the design, synthesis, and the peptidyl-prolyl isomerase (PPIase or rotamase) inhibitory activity of novel bicyclic diamide compounds that are neuroprotective and/or neurotrophic agents (i.e. compounds capable of stimulating growth or proliferation of nervous tissue) and that bind to immunophilins such as FKBP12 and inhibit their rotamase activity. This invention also relates to pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: November 16, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gene Michael Dubowchik, David Paul Provencal
  • Patent number: 6774134
    Abstract: The present invention concerns antiviral compounds, their methods of preparation and their compositions, and use in the treatment of viral infections. More particularly, the invention provides heterocyclic substituted 2-methylbenzimidazole derivatives for the treatment of respiratory syncytial virus infection.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: August 10, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kuo-Long Yu, Rita L. Civiello, Keith D. Combrink, Hatice Belgin Gulgeze, Ny Sin, Xiangdong Wang, Nicholas Meanwell, Brian Lee Venables, Yi Zhang, Bradley C. Pearce, Zhiwei Yin, Jan Willem Thuring
  • Patent number: 6750246
    Abstract: The present invention concerns novel taxane derivatives, their use as antitumor agents, and pharmaceutical formulations. The invention claims compounds of formula I and the use of compounds of formula I or pharmaceutical salts thereof as oral drugs for the treatment of human or veterinary disease. in which: R is phenyl, isopropyl, or tert butyl; R1 is —C(O)Rz in which Rz is (CH3)3CO—, (CH3)3CCH2—, CH3(CH2)3O—, cyclobutyl-, cyclohexyloxy, or (2-furyl); R2 is CH3C(O)O—.
    Type: Grant
    Filed: November 14, 2000
    Date of Patent: June 15, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: John F. Kadow, Harold Mastalerz, Qiufen May Xue, Steven Hansel, Mary Edson Zoeckler, William C. Rose, James G. Tarrant
  • Patent number: 6737428
    Abstract: The novel crystalline bis hydrochloride monohydrate salt having the formula and pharmaceutical dosage forms thereof is provided having use in the treatment of respiratory syncytial viral infection.
    Type: Grant
    Filed: December 5, 2002
    Date of Patent: May 18, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Christoph Gesenberg, David Paul Provencal, Srinivasan Venkatesh, Hua Wang
  • Patent number: 6649644
    Abstract: This invention relates to a method of treating human immunodeficiency virus (HIV) infection in a mammal comprising administering to the mammal a therapeutically effective amount of a combination of: (i) at least one cytotoxic agent and (ii) at least one non-nucleoside reverse transcriptase HIV inhibitor (NNRTI). This invention also relates to a method of treating chronic viral infections comprising administering to the mammal a therapeutically effective amount of a combination of: (i) at least one cytotoxic agent and (ii) at least one antiviral agent.
    Type: Grant
    Filed: October 12, 1999
    Date of Patent: November 18, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventor: Bruce D. Korant
  • Patent number: 6632819
    Abstract: The invention comprises compounds of the class of azaindole piperazine diamide derivatives, compositions thereof and their use as anti-viral agents, and particularly for treating HIV infection.
    Type: Grant
    Filed: October 10, 2002
    Date of Patent: October 14, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Owen B. Wallace, Zhongxing Zhang, Nicholas A. Meanwell, John A. Bender
  • Patent number: 6573262
    Abstract: The invention comprises substituted indoleoxoacetic piperazine derivatives of general Formula I, compositions thereof and their use as antiviral agents, and particularly for treating HIV infection.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: June 3, 2003
    Assignee: Bristol-Myers Sqibb Company
    Inventors: Owen B. Wallace, Tao Wang, Kap-Sun Yeung, Bradley C. Pearce, Nicholas A. Meanwell, Zhilei Qiu, Haiquan Fang, Qiufen May Xue, Zhiwei Yin
  • Patent number: 6506738
    Abstract: The present invention concerns antiviral compounds, their compositions, and use in the treatment of viral infections. More particularly, the invention provides benzimidazolone derivatives for the treatment of respiratory syncytial virus infection.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: January 14, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kuo-Long Yu, Rita Civiello, Keith Combrink, Hatice Belgin Gulgeze, Bradley C. Pearce, Xiangdong Wang, Nicholas A. Meanwell, Yi Zhang
  • Patent number: 6489338
    Abstract: The present invention concerns antiviral compounds, their methods of preparation and their compositions, and use in the treatment of viral infections. More particularly, the invention provides imidazopyridine and imidazopyrimidine derivatives (Formula I) for the treatment of respiratory syncytial virus infection.
    Type: Grant
    Filed: April 23, 2001
    Date of Patent: December 3, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kuo-Long Yu, Rita L. Civiello, Keith D. Combrink, Hatice Belgin Gulgeze, Ny Sin, Xiangdong Wang, Nicholas A. Meanwell, Brian Lee Venables
  • Patent number: 6476034
    Abstract: The invention comprises compounds of the class of azaindole piperazine diamide derivatives, compositions thereof and their use as anti-viral agents, and particularly for treating HIV infection.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: November 5, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Owen B. Wallace, Zhongxing Zhang, Nicholas A. Meanwell, John A. Bender
  • Patent number: 6455575
    Abstract: The present invention concerns antitumor compounds. More particularly, the invention provides novel taxane derivatives, pharmaceutical compositions thereof, and their use as antitumor agents.
    Type: Grant
    Filed: June 6, 1997
    Date of Patent: September 24, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jerzy Golik, Dolatrai Vyas, John J. Wright, Henry Wong, John F. Kadow, John K. Thottathil, Wen-Sen Li, Murray A. Kaplan, Robert K. Perrone, Mark D. Wittman
  • Patent number: 6362217
    Abstract: The present invention concerns novel 7-deoxy taxane derivatives their use as antitumor agents, and pharmaceutical formulations.
    Type: Grant
    Filed: March 8, 2001
    Date of Patent: March 26, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: John F. Kadow, Wendy S. Schwartz, Paul M. Scola, Qiufen May Xue, Mark D. Wittman, Mu-Jen Wu
  • Patent number: 6287827
    Abstract: Fermentation of Nocardia sp. ATCC-202099 in the presence of a halogen- or hydroxy-substituted tryptophan precursor yields a novel corresponding halogen- or hydroxy-substituted nocathiacin compound which has broad spectrum antibiotic activity against Gram-positive bacteria and has in vivo efficacy in animals.
    Type: Grant
    Filed: May 1, 2000
    Date of Patent: September 11, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wenying Li, John E. Leet, Kin S. Lam
  • Patent number: 6281342
    Abstract: Disclosed are novel pradimicin compounds which possess antifungal activity and, preferably, improved water solubility. The compounds of the invention are prepared by modifying the 4′-amino or 4′-alkylamino moieties of known pradimicin compounds.
    Type: Grant
    Filed: May 12, 1994
    Date of Patent: August 28, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventors: Hajime Kamachi, Minoru Hirano, Shinji Masuyoshi